Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,359 across all filing types
Latest filing 2025-12-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于出售子公司股权进展暨完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress and completion of the sale of a subsidiary's equity and the related business registration change. It details the transaction overview, the board meeting approval, and the completion of the equity transfer registration. This is a capital or financing activity update rather than a full financial report or other types of filings. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on a specific transaction update, confirming the classification.
2025-12-22 Chinese
亚宝药业集团股份有限公司2025年三季度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution announcement for the third quarter of 2025 by 亚宝药业集团股份有限公司. It details the dividend per share, total dividend amount, and the approval process involving the board and upcoming shareholder meeting. The document is short (1004 characters) and focuses on dividend distribution details rather than presenting full financial statements or comprehensive financial analysis. It is not an earnings release or interim report but specifically announces the dividend amount and related shareholder meeting information. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2025-12-19 Chinese
亚宝药业集团股份有限公司关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary shareholders meeting (临时股东会) of 亚宝药业集团股份有限公司. It details the meeting date, voting methods, agenda items (including the 2025 Q3 profit distribution plan), registration procedures, and proxy authorization form. There is no financial data or report content included, only the announcement and procedural information for the shareholders meeting. The document length is 3149 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit votes and participation in the meeting.
2025-12-19 Chinese
亚宝药业集团股份有限公司第九届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 亚宝药业集团股份有限公司 (Yabao Pharmaceutical Group Co., Ltd.). It includes approval of the 2025 third quarter profit distribution plan and the proposal to convene the 2026 first extraordinary shareholders meeting. The document is titled as a board meeting resolution announcement and contains voting results and decisions made by the board. It does not contain full financial statements or detailed financial analysis, nor is it a report itself. It is not a notice of dividend amount alone, but a board resolution including dividend distribution approval. Therefore, it fits best under Board/Management Information (MANG) as it announces board decisions and resolutions.
2025-12-19 Chinese
亚宝药业集团股份有限公司关于GLX002获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 亚宝药业集团股份有限公司 regarding the approval of a clinical trial for a new drug (GLX002) by the National Medical Products Administration (国家药品监督管理局). It details the drug's basic information, regulatory approval, and risk warnings. The document is short (1123 characters) and serves as a regulatory announcement about a specific event (clinical trial approval). It does not contain financial data, management discussion, or detailed financial reports. It is not an annual or interim report, earnings release, or any form of financial filing. It is also not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-12-17 Chinese
亚宝药业集团股份有限公司关于年度审计机构更换签字注册会计师及质量控制复核人的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding the change of the signing certified public accountants and quality control reviewers for the 2025 annual audit. It references the audit firm and personnel changes but does not contain any financial statements or audit results. The document length is short (1364 characters) and it is an announcement about audit personnel changes rather than the audit report itself. Therefore, it fits the category of Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports. FY 2025
2025-12-12 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.